CHOSA.ST CHOSA Oncology AB

Healthcare Biotechnology Stockholm Exchange
0.5440 SEK
Close of Oct 31, 2026
0.4090 1.35
Market cap
SEK 49.7M
P/E
-
P/B
2.28x
ROE
-47.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CHOSA.ST undervalued?

Graham number

The Graham number of CHOSA Oncology AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CHOSA Oncology AB fundamental analysis

No fundamental analysis for CHOSA Oncology AB yet.

CHOSA Oncology AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CHOSA Oncology AB

Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA. It provides Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 …

Full company profile